In this study, higher intakes of dairy milk were correlated with greater risk of breast cancer, when adjusted for soy intake.
The FDA approved a supplemental new drug application for neratinib in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received at least 2 prior anti-HER2-based regimens in the metastatic setting.
A survey study documented slow progress in the advancement of palliative care programs and emphasized that access to timely palliative care continues to be a challenge for patients with cancer, especially those at non-National Cancer Institute cancer centers.
In this study, increased radiation dose was correlated with an increase in fatigue and dyspnea, as well as a decrease in physical activity, particularly in lung cancer or lymphoma.
Researchers found that poor infiltration of the tumor by immune cells, low activity from available T-cells, a lack of immune-stimulating neoantigens, and multiple immune-suppressing pathways all combine to dampen responses to immunotherapy in this disease landscape.
LUNGevity Foundation released a Lung Cancer Scorecard to examine how effectively (or ineffectively) states are addressing lung cancer.
The FDA accepted a biologics license application for the fixed-dose combination of pertuzumab and trastuzumab with hyaluronidase, administered by subcutaneous injection in combination with IV chemotherapy, for the treatment of eligible patients with HER2-positive breast cancer.
The FDA accepted a supplemental new drug application for niraparib, treating women with advanced ovarian cancer who responded to platinum-based chemotherapy regardless of biomarker status, based on data from the PRIMA study.
The FDA recently granted priority review to Takeda’s supplemental new drug application for brigatinib to treat ALK-positive metastatic non-small cell lung cancer.
These data, in combination with durable complete responses and overall survival data, suggested that tisagenlecleucel improved health-related quality of life in adult patients with relapsed or refractory diffuse large B-cell lymphoma who respond to treatment.
Karen Kelly, MD, sat down to discuss her presentation on when to start immunotherapy in a real world, patient setting.
In this study, the skin cancer rates were higher among gay and bisexual men, compared with heterosexual men, but lower among bisexual women than heterosexual women.
Walter Curran, MD, detailed his presentation on immunotherapy and radiation therapy, and how integrating the 2 treatment options presents an exciting opportunity moving forward.
In this study, researchers suggested that patients who play a more active role in making decisions about their prostate cancer surgery are less likely to experience “decision regret” about their choices.
A new tool, in combination with those already existing, could distinguish between patients with malignant and benign ovarian masses, as well as those with a benign ovarian mass and normal ovaries.